Drug Information

Drug General Information
Drug ID
D0Y1XT
Former ID
DNC003717
Drug Name
SC-44463
Drug Type
Small molecular drug
Indication Discovery agent Terminated [1]
Structure
Download
2D MOL

3D MOL
Formula
C19H29N3O5
Canonical SMILES
CC(C)CC(CC(=O)NO)C(=O)NC(CC1=CC=C(C=C1)OC)C(=O)NC
InChI
1S/C19H29N3O5/c1-12(2)9-14(11-17(23)22-26)18(24)21-16(19(25)20-3)10-13-5-7-15(27-4)8-6-13/h5-8,12,14,16,26H,9-11H2,1-4H3,(H,20,25)(H,21,24)(H,22,23)/t14-,16+/m1/s1
InChIKey
QYZPDCGWIJYZMN-ZBFHGGJFSA-N
PubChem Compound ID
128564
Target and Pathway
Target(s) MMP-9 Target Info Inhibitor [2]
Neutrophil collagenase Target Info Inhibitor [2]
Stromelysin-1 Target Info Inhibitor [3]
72 kDa type IV collagenase Target Info Inhibitor [4]
Matrilysin Target Info Inhibitor [4]
Aggrecanase Target Info Inhibitor [2]
Interstitial collagenase Target Info Inhibitor [4]
ADAMTS-4 Target Info Inhibitor [2]
KEGG Pathway TNF signaling pathway
Leukocyte transendothelial migration
Estrogen signaling pathway
Hepatitis B
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Bladder cancerhsa04668:TNF signaling pathway
Rheumatoid arthritishsa04670:Leukocyte transendothelial migration
GnRH signaling pathway
Bladder cancerhsa04310:Wnt signaling pathwayhsa03320:PPAR signaling pathway
Bladder cancer
Rheumatoid arthritis
NetPath Pathway ID Signaling Pathway
TWEAK Signaling Pathway
Leptin Signaling Pathway
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling Pathway
IL4 Signaling PathwayNetPath_22:Leptin Signaling Pathway
TCR Signaling Pathway
ID Signaling PathwayNetPath_8:Wnt Signaling PathwayNetPath_13:IL1 Signaling Pathway
EGFR1 Signaling Pathway
Wnt Signaling Pathway
PANTHER Pathway Alzheimer disease-presenilin pathway
Plasminogen activating cascade
CCKR signaling map STP00004:Alzheimer disease-presenilin pathwayP00050:Plasminogen activating cascade
CCKR signaling map STP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
Wnt signaling pathway
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
Pathway Interaction Database LPA receptor mediated events
Plasma membrane estrogen receptor signaling
Osteopontin-mediated events
Validated transcriptional targets of AP1 family members Fra1 and Fra2
Validated targets of C-MYC transcriptional activation
CXCR4-mediated signaling events
amb2 Integrin signaling
Syndecan-4-mediated signaling events
AP-1 transcription factor network
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Syndecan-1-mediated signaling events
Regulation of nuclear beta catenin signaling and target gene transcription
FGF signaling pathwayajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
p75(NTR)-mediated signaling
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
Angiopoietin receptor Tie2-mediated signaling
Direct p53 effectors
ATF-2 transcription factor network
FOXM1 transcription factor network
Syndecan-2-mediated signaling eventsajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
Syndecan-1-mediated signaling eventsendothelinpathway:Endothelins
Glucocorticoid receptor regulatory network
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Assembly of collagen fibrils and other multimeric structures
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
Activation of Matrix MetalloproteinasesR-HSA-1442490:Collagen degradation
EGFR Transactivation by GastrinR-HSA-1442490:Collagen degradation
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Assembly of collagen fibrils and other multimeric structuresR-HSA-1474228:Degradation of the extracellular matrix
O-glycosylation of TSR domain-containing proteinsR-HSA-1442490:Collagen degradation
Basigin interactions
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)R-HSA-1474228:Degradation of the extracellular matrix
O-glycosylation of TSR domain-containing proteins
WikiPathways Endochondral Ossification
IL1 and megakaryotyces in obesity
Mammary gland development pathway - Involution (Stage 4 of 4)
Activation of Matrix Metalloproteinases
Degradation of collagen
Spinal Cord Injury
AGE/RAGE pathway
TWEAK Signaling Pathway
Angiogenesis
Osteopontin Signaling
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
Gastrin-CREB signalling pathway via PKC and MAPK
Oncostatin M Signaling Pathway
Matrix MetalloproteinasesWP399:Wnt Signaling Pathway and Pluripotency
Matrix MetalloproteinasesWP474:Endochondral Ossification
Vitamin D Receptor PathwayWP366:TGF beta Signaling Pathway
Bladder Cancer
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell surface interactions at the vascular wall
References
REF 1Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007717)
REF 2J Med Chem. 2001 Oct 11;44(21):3347-50.Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
REF 3Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
REF 4J Med Chem. 2003 Jul 31;46(16):3514-25.A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.